EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

Amendments of the European Union (EU) pharmacovigilance legislation that were adopted in October 2012 came into force on Monday 28 October 2013. These changes, which cover various aspects of the legislation, aim to further strengthen the protection of patient health by increasing the ability of the European medicines network to take prompt and appropriate regulatory action.

To view these amendments, please click here.

Ti view the pharmacovigilance legislation, please click here.







Recent news

» COVID-19 vaccines for myeloma patients: what you need to know

» Horizon2020 CARAMBA Myeloma Pipeline information sheet now available in five languages

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.